Effua Usuf1, Henry Badji1, Abdoulie Bojang1, Sheikh Jarju1, Usman Nurudeen Ikumapayi1, Martin Antonio1,2,3, Grant Mackenzie1,3,4, Christian Bottomley5. 1. Medical Research Council Unit, Fajara, The Gambia. 2. Microbiology and Infection Unit, University of Warwick, Coventry, UK. 3. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. 4. Murdoch Children's Research Institute, Melbourne, Vic., Australia. 5. Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
Abstract
OBJECTIVE: To evaluate pneumococcal colonisation before and after the introduction of pneumococcal conjugate vaccine (PCV) in eastern Gambia. METHODS: Population-based cross-sectional survey of pneumococcal carriage between May and August 2009 before the introduction of PCV into the Expanded Program on Immunization. Nasopharyngeal swabs were collected from all household members, but in selected households, only children aged 6-10 years were swabbed. This age group participated in an earlier trial of a nine-valent PCV between 2000 and 2004. RESULTS: The prevalence of nasopharyngeal pneumococcal carriage in 2933 individuals was 72.0% in underfives (N = 515), 41.6% in children aged 5-17 (N = 1508) and 13.0% in adults ≥18 (N = 910) years. The age-specific prevalence of serotypes included in PCV7, PCV10 and PCV13 was 24.7%, 26.6% and 46.8% among children <5 years of age; 8.5%, 9.2% and 17.7% among children 5-17 years; and 2.5%, 3.3% and 5.5% among adults ≥18 years. The most common serotypes were 6A (13.1%), 23F (7.6%), 3 (7.3%), 19F (7.1%) and 34 (4.6%). There was no difference in the overall carriage of pneumococci between vaccinated and unvaccinated children 8 years after the primary vaccination with three doses of PCV (48.3% vs. 41.1%). CONCLUSION: Before the introduction of PCV, serotypes included in PCV13 accounted for about half the pneumococcal serotypes in nasopharyngeal carriage. Thus, the potential impact of PCV13 on pneumococcal disease in the Gambia is substantial.
OBJECTIVE: To evaluate pneumococcal colonisation before and after the introduction of pneumococcal conjugate vaccine (PCV) in eastern Gambia. METHODS: Population-based cross-sectional survey of pneumococcal carriage between May and August 2009 before the introduction of PCV into the Expanded Program on Immunization. Nasopharyngeal swabs were collected from all household members, but in selected households, only children aged 6-10 years were swabbed. This age group participated in an earlier trial of a nine-valent PCV between 2000 and 2004. RESULTS: The prevalence of nasopharyngeal pneumococcal carriage in 2933 individuals was 72.0% in underfives (N = 515), 41.6% in children aged 5-17 (N = 1508) and 13.0% in adults ≥18 (N = 910) years. The age-specific prevalence of serotypes included in PCV7, PCV10 and PCV13 was 24.7%, 26.6% and 46.8% among children <5 years of age; 8.5%, 9.2% and 17.7% among children 5-17 years; and 2.5%, 3.3% and 5.5% among adults ≥18 years. The most common serotypes were 6A (13.1%), 23F (7.6%), 3 (7.3%), 19F (7.1%) and 34 (4.6%). There was no difference in the overall carriage of pneumococci between vaccinated and unvaccinated children 8 years after the primary vaccination with three doses of PCV (48.3% vs. 41.1%). CONCLUSION: Before the introduction of PCV, serotypes included in PCV13 accounted for about half the pneumococcal serotypes in nasopharyngeal carriage. Thus, the potential impact of PCV13 on pneumococcal disease in the Gambia is substantial.
Authors: Ann Lindstrand; Joan Kalyango; Tobias Alfvén; Jessica Darenberg; Daniel Kadobera; Freddie Bwanga; Stefan Peterson; Birgitta Henriques-Normark; Karin Källander Journal: PLoS One Date: 2016-11-09 Impact factor: 3.240
Authors: Miwako Kobayashi; Laura M Conklin; Godfrey Bigogo; Geofrey Jagero; Lee Hampton; Katherine E Fleming-Dutra; Muthoni Junghae; Maria da Gloria Carvalho; Fabiana Pimenta; Bernard Beall; Thomas Taylor; Kayla F Laserson; John Vulule; Chris Van Beneden; Lindsay Kim; Daniel R Feikin; Cynthia G Whitney; Robert F Breiman Journal: BMC Infect Dis Date: 2017-01-05 Impact factor: 3.090
Authors: Emma L Smith; India Wheeler; Hugh Adler; Daniela M Ferreira; Raquel Sá-Leão; Osman Abdullahi; Ifedayo Adetifa; Sylvia Becker-Dreps; Susanna Esposito; Helmia Farida; Rama Kandasamy; Grant A Mackenzie; J Pekka Nuorti; Susan Nzenze; Shabir A Madhi; Omar Ortega; Anna Roca; Dodi Safari; Frieder Schaumburg; Effua Usuf; Elisabeth A M Sanders; Lindsay R Grant; Laura L Hammitt; Katherine L O'Brien; Prabhu Gounder; Dana J T Bruden; Michelle C Stanton; Jamie Rylance Journal: J Infect Date: 2020-06-17 Impact factor: 6.072
Authors: Neil French; Robert S Heyderman; Todd D Swarthout; Claudio Fronterre; José Lourenço; Uri Obolski; Andrea Gori; Naor Bar-Zeev; Dean Everett; Arox W Kamng'ona; Thandie S Mwalukomo; Andrew A Mataya; Charles Mwansambo; Marjory Banda; Sunetra Gupta; Peter Diggle Journal: Nat Commun Date: 2020-05-06 Impact factor: 14.919
Authors: Todd D Swarthout; Ana Ibarz-Pavon; Gift Kawalazira; George Sinjani; James Chirombo; Andrea Gori; Peter Chalusa; Farouck Bonomali; Roseline Nyirenda; Edwin Bulla; Comfort Brown; Jacquline Msefula; Marjory Banda; Jean Kachala; Charles Mwansambo; Marc Yr Henrion; Stephen B Gordon; Neil French; Robert S Heyderman Journal: BMJ Open Date: 2021-06-17 Impact factor: 2.692